Summary
Clinicians recognise nonsteroidal anti-inflammatory drugs (NSAIDs) as valuable first-line agents in the treatment of rheumatic disorders and as dangerous irritants to the gastrointestinal tract. This has led to questions about the economic impact of NSAID-induced gastropathy in populations.
This study estimated the 1992 costs of NSAID-associated gastropathy episodes, and calculated an iatrogenic cost factor for NSAID-associated gastropathy among elderly members of a health maintenance organisation (HMO), the Northwest Region of Kaiser Permanente.
Using data retrieved from automated databases and from medical records, NSAID and antiulcer drug costs were calculated, and estimates were made of the incidence rates of inpatient and outpatient NSAID-associated gastropathies, the services provided to treat them, and the cost of those services.
Kaiser Permanente Northwest spent $US0.35 for each $US1.00 spent on NSAID therapy for the elderly, an iatrogenic cost factor of 1.35. The estimated average treatment per NSAID-associated gastropathy episode was $US2172. The average outpatient pharmacy cost per elderly NSAID user was $US80 and estimated average NSAID-associated treatment cost per elderly NSAID user was $US43.
Although the findings were specific to the HMO because of the databases used, the methodology employed and the drug formulary influence on NSAID selection, they show that a substantial amount of resources were used to treat NSAID-induced gastropathies in the elderly, underscoring the risk of prescribing NSAIDs and reinforcing the need for their prudent use in elderly patients.
Similar content being viewed by others
References
Zeidler H. Epidemiology and economics of NSAID-induced gastropathy. Scand J Rheumatol 1992; 21 Suppl. 92: 3–8
Baum C, Kennedy DL, Forbes MB. Utilization of anti-inflammatory drugs. Arthritis Rheum 1985; 28: 686–92
Graham DY. Prevention of gastroduodenal injury induced by chronic nonsteroidal anti-inflammatory drug therapy. Gastroenterology 1989; 96: 675–81
Bradley JD, Brandt KD, Katz BP, et al. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325: 87–91
Bradley JD, Brandt KD, Kalasinski LA, et al. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. J Rheumatol 1992; 19: 1950–4
Parr G, Darekar B, Fletcher A, et al. Joint pain and the quality of life; results of a randomized trial. Br J Clin Pharmacol 1989; 27: 235–42
Beard K, Walker AM, Perera DR, et al. Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. Arch Intern Med 1987; 147: 1621–3
Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787–96
Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359–63
Henry D, Lim LL-Y, Rodriguez LAG, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative metaanalysis. BMJ 1996; 313: 1563–6
Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 2061–5
Knill-Jones RP. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville. Scand J Rheumatol 1992; 21 Suppl. 96: 59–62
Carrin GJ, Torfs KE. Economic evaluation of prophylactic treatment with misoprostol in osteoarthritic patients treated with NSAIDs: the case of Belgium. Rev Epidemiol Sante Publique 1990; 38: 187–99
de Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. Scand J Rheumatol 1992; 21 Suppl. 96: 49–53
de Pouvourville G, Bader JP. Cost-effectiveness of preventive treatment with misoprostol in NSAID-related gastric ulcers. Gastroenterol Clin Biol 1991; 15: 399–404
Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988; 88 Suppl. 2A: 20–4
Hochberg MC. Association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal disease: epidemiologic and economic considerations. J Rheumatol 1992; 19 Suppl. 36: 63–7
Kolodny AL, Klipper A. Final report on the cost of treating arthritic disease: comparison between salicylates and non-salicylate nonsteroidal anti-inflammatory drugs. Semin Arthritis Rheum 1985; 14 Suppl. 1: 20–4
Loeb DS, Ahlquist DA, Talley NJ. Management of gastroduodenopathy associated with use of nonsteroidal antiinflammatory drugs. Mayo Clin Proc 1992; 67: 354–64
Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch Intern Med 1996; 156: 1530–6
Stucki G, Johannesson M, Liang MH. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with arthritis? A review of conflicting economic evaluations. Arch Intern Med 1994; 154: 2020–5
de Pouvourville G, Tasch RF. The economic consequences of NSAID-induced gastrointestinal damage. Eur J Rheumatol Inflamm 1993; 13: 33–40
Gabriel SE, Campion ME, O’Fallon WM. A cost-utility of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1994; 37: 331–41
Hsiao WC, Couch N, Causino N, et al. Resource-based relative values. JAMA 1988; 260: 2347–53
Penn RL, Johnson RE, Vogt TM. How the CHR RVS was developed, and analysis of the cost of production of RVS units in KP. Portland (OR): Center for Health Research, Kaiser Permanente, 1983
US Bureau of the Census. Statistical abstract of the United States. 115th ed. Washington, DC: US Bureau of the Census, 1995: 494
US Bureau of the Census. Statistical abstract of the United States. 114th ed. Washington, DC: US Bureau of the Census, 1994: 435
Hornbrook MC, Goodman MJ. Assessing relative health plan risk with the RAND-36 health survey. Inquiry 1995; 32: 56–74
Fries JF, Spitz PW, Williams CA, et al. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990; 33: 121–30
Fries JF, Williams CA, Bloch DA. The relative toxicity of non-steroidal anti-inflammatory drugs. Arthritis Rheum 1991; 34: 1353–60
Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257–63
Skeith KJ, Wright M, Davis P. Differences in NSAID tolerability profiles — fact or fiction? Drug Saf 1994; 10: 183–95
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnson, R.E., Hornbrook, M.C., Hooker, R.S. et al. Analysis of the Costs of NSAID-Associated Gastropathy. Pharmacoeconomics 12, 76–88 (1997). https://doi.org/10.2165/00019053-199712010-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199712010-00008